Autoimmune Hepatitis - Falk · PDF fileAutoimmune Hepatitis Stephan Kanzler II. Department of Medicine Leopoldina Hospital Schweinfurt, Germany ... • LP antibodies first descibed

Autoimmune Hepatitis

Stephan KanzlerII. Department of MedicineLeopoldina HospitalSchweinfurt, Germany

Falk Symposium 160, Portoroz - 16.06.2007

Autoimmune Liver Diseases

OVERLAPAIH PBC/PSC


Inactivehepatitis

Chronic active hepatitis

Acutehepatitis

Fulminanthepatitis

Intensity of immune response

Immunopathogenesis of AIH(Excessive autoimmune response in genetically

predisposed subjects - reason??)

70 (48%)17 (30%)28 (18%)B8-DR3-DQ2

84 (57%)30 (53%)42 (27%)DQ2

24 (16%)15 (26%)17 (11%)DR13

11 (7%)10 (18%)17 (11%)DR11

23 (15%)9 (16%)20 (13%)DR7

64 (43%)13 (23%)68 (44%)DR4

77 (52%)17(30%)70 (45%)DR3

73 (49%)18 (32%)64 (41%)B8

North American type I AIH (n=149)

Italian type 1 AIH (n= 57)

German type 1 AIH (n = 156)

HLA

Teufel et al. WJG 2006

Undulating spontaneous course of AIH

AST Bilirubine

Prednisolone

Azathioprine

Significantly reduced life expectancy in patients with untreated AIH!!

Royal Free Hospital Trial 1972

Epidemiology of AIH

• Prevalent in all countries and races

• Prevalence in europe: about 1 : 10.000

• 75 % women

• Age of manifestation: 2 - 75 years, median 45

Age distribution of AIH-patients at initial diagnosis

Absolute frequency

Age in years

Autoimmune Hepatitis: clinical aspects

• Frequently slow onset, however: 25 % with acute (icteric) onset

• Fluctuating course

• Arthalgias and fatigue

• Further autoimmunopathies in personal or family history

Toxic liver damage Hepatitis B Hepatitis C

Fatty liver disease Wilson disease

Hämochromatosis .......................................

PSC PBC

Differential diagnosis

There is no single test prooving the diagnosis of AIH (exception SLA/LP?)!

Diagnosis of AIH: Scoring-System of the IAIHG

Alvares et al. J Hepatol. 1999

• Female gender + 2

• AP : AST-ratio< 1,5 + 21,5 - 3 0> 3 - 2

• IgG / γ-globuline elevation> 2 + 31,5 - 2 + 21 - 1,5 + 1< 1 0

• ANA, SMA or LKM-1> 1 : 80 + 31 : 80 + 21 : 40 + 1< 1 : 40 0AMA > 1 : 40 - 4

• Viral hepatitis (HBsAg, anti-HCV)positive - 3negative + 3



• Use of medicamentsPositive - 4Negative + 1

• Consumption of alcohol< 25 g / d + 2> 60 g / d - 2

• Other autoantibodies (SLA/LP, ANCA, LC1) + 2

• HLA-DR3 or DR4 + 2

• Other autoimmune diseases (patient/family) + 2



• Liver histologyInterface hepatitis + 3Lymphoplasmacellular infiltrates + 1Rosetting of hepatocytes + 1No of the above changes - 5Bile duct pathologies - 3

• Success of therapyComplete + 2Relapse after withdrawal + 3



• Before treatment (immunosuppression):„Definite“ AIH > 15 points„Probable“ AIH 10 - 15 points

• After treatment (immunosuppression):„Definite“ AIH > 17 points„Probable“ AIH 12 - 17 points



Diagnose der AIH: vereinfachte Hauptkriterien

• Selektive IgG Erhöhung

• Autoantikörper (ANA, SMA, SLA/LP, LKM)

• Histologie einer chronischen Hepatitis

• Ausschluß Virushepatitis

3 von 4 Kriterien sollten erfüllt sein

Diagnosis of AIH: Simplified main criteria I

• IgG (γ-Globuline) elevation 1

• IgG > 18.5 g/l 2

• ANA, SMA, LKM > 1:40 1

• ANA, SMA, LKM > 1:80 2

• Histology compatible with AIH 1

• Histology typical for AIH 2

• Exclusion of viral hepatitis 2

> 5 points = AIH probableHennes et al. for the IAHG; AASLD 2005

• Response to immunosuppressive therapy

• Relapse after discontinuation of immunosuppressive therapy

Diagnosis of AIH: Simplified main criteria II

Hennes et al. for the IAHG; AASLD 2005

Autoantibodies in AIH

• ANA: Anti-Nuclear Antibodies

• SMA: Smooth Muscle Antibodies

• LKM: Liver Kidney Microsomal Antibodies

• SLA/LP: Soluble Liver Antigen/Liver-Pancreas

• Other: (ANCA, ASGPR, LC1, ...) - unspecific

Autoantibodies in patients with hepatitis

(839 consecutive outpatients, I. Dept. of Medicine, Mainz)

AIH Hepatitis B Hepatitis C

keineSLA + andereSLALKMANA + SMASMAANA

Lohse et al.; Z. Gastroenterol. 1995

ANAAnti-Nuclear Antibodies

• Found in 40 - 50% of all AIH-patients• Against multiple antigens• High titers (> 1:80) and / or combination with

SMA diagnostically helpful• Immunofluorescence is gold standard

Immunofluorescence: ANA

SMAAnti-Smooth Muscle Antibodies

• Found in about 40% of all AIH-patients

• Main antigen: F-actin

• High titers (> 1:80) or combination with ANA dignostically helpful

• Immunofluorescence is gold standard

LKMLiver-Kidney-Microsomal Antibodies

• Rare! (<< 5%)

• Mostly in childhood

• Target antigen: cytochrome p450 2D6

• Immunofluorescence and ELISA

• Type II AIH; run a more severe course?

Immunohistology: LKM

SLA/LPAnti-Soluble Liver Antigen / Liver

Pancreas

• LP antibodies first descibed in 1981 (Berg et al.)

• SLA antibodies first described in 1987 (Manns et al.)

• SLA and LP are the same antigen (Wies et al. 2000)

• About 20 - 30 % of all AIH-patients

• Very high disease specificity (type III AIH)

Prevalence of SLA/LP autoantibodies in AIH

Germanyn = 108

81%

19%

SLA/LP-positiveSLA/LP-negative

USAn = 149

15%

85%

Japann = 30

7%

93%

Braziln = 132

17%

83%

Baeres et al. Hepatology 2000; 32: 238Kanzler et al. J Hepatol 1999; 31: 635

Staging (mini-)laparoscopy in patients with AIH

Low complication rate / high diagnostic yield

About 30 % of all AIH-patients have liver cirrhosis at initial diagnosis!


=

Chronic Disease

Aim of treatment

• Normalisation of transaminases + IgG

• Histologically no or minimal disease activity

• No significant side effects of therapy!

Therapy of AIH: Induction therapy

• Prednisolone – Initially 1 mg / kg

– weekly reduction

– from 20 mg/d on reduction in 4-weekly interval

– Vit. D + calcium

• Azathioprine 1 - 1.5 mg /kg

Response to immunosuppressive therapy

(after 6 months, n = 103)

Incomplete Remission

6.9%

No Remission1.9%

Complete Remission

91.2 %

Kanzler et al. Z Gastroenterol 2001.

AIH - Maintenance therapy

50 (-100) mg Azathioprine / d +/- 5 (-10) mg Prednisolone / d or 50 - 150 mg Azathioprine / d

Johnson et al.: NEJM 1995

Relapse under maintenance therapy (Mean observation period 95 months, n = 103)

Relapse35.9%

Remission64.1%


Relapse after discontinuation of immunosuppressive therapy

(n = 28)


Stable Remissio

nRelaps

e

Relapse of AIH after discontinuation of immunsuppressive therapy

Prob

abili

ty o

f sta

ble

rem

issi

on a

fter

disc

ontin

uatio

n of

imm

uno-

supp

ress

ive

ther

apy

(%)

100

75

50

25

0

n = 10 n = 12 n = 6

67 %

17 % 10 %

1-2 years2-4 years

> 4 years


Duration of stable remission

Alternative therapeutic options in AIH

• Mofetilmycofenolate (MMF) 1 - 2 g / d– Hennes et al. submitted

• Cyclophosphamide 1 - 2 mg / kg / d– Kanzler et al. Z Gastroenterol 1997

• Budenoside ?? (not in cirrhotics!)– Wiegand et al. Liver International 2005

– Large international multicenter-study recently closed

• CsA, FK 506

• Anti-TNF therapy (??)

AIH and HepatoCellular Carcinoma (HCC)

• Follow-up of 278 patients with AIH in Mainz

• 89 Patienten (32%) with liver cirrhosis

• 431 observation years of AIH-associated liver cirrhosis: No patient developed HCC (despite of immunosuppression)!

• Since 1990 referal of three patients with AIH and HCC (exclusion of concomittant liver disease)

Teufel et al. Submitted

Survival of AIH-patients under immunosuppressive therapy (103 patients, mean observation period 95 months)Su

rviv

al ra

te [%

]

Years

AIH-patients

General population

Kanzler et al.: Z Gastroenterol 2001; 39:339-348

Overlap-Syndromes: Therapy

Activity of AIH determines the intensity of immunosuppressive therapy, since untreated AIH has the worst prognosis

OVERLAPAIH PBC/PSC

Documents

Autoimmune Hepatitis - Falk · PDF fileAutoimmune Hepatitis Stephan Kanzler II. Department of Medicine Leopoldina Hospital Schweinfurt, Germany ... • LP antibodies first descibed